Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy [Yahoo! Finance]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: Yahoo! Finance
Following the US Food and Drug Administration's (FDA) call to greenlight the drug, Komzifti will now be available to adult patients with relapsed or refractory acute myeloid leukaemia (r/r AML). The targeted therapy is specifically indicated for patients with a susceptible Nucleophosmin 1 (NPM1) mutation. Komzifti obtained the approval based on the results of the Phase III KOMET-001 study (NCT04067336), which saw the drug trigger complete remission (CR) plus CR with partial haematological recovery (CRh) in 21.4% of patients. This effect was sustained over a median duration of five months. As Komzifti enters the market, it becomes the first once-daily oral menin inhibitor to gain FDA approval in NPM1-mutated r/r AML – an indication with limited treatment options that is commonly associated with poor patient prognoses. It is currently estimated that just under one-third of AML cases present a NPM1 founder mutation. Within this patient population, around 70% of patients will rel
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Kura Oncology: A Cautious Buy [Seeking Alpha]Seeking Alpha
- Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia [Yahoo! Finance]Yahoo! Finance
- Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid LeukemiaGlobeNewswire
- Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data [Seeking Alpha]Seeking Alpha
KURA
Earnings
- 11/4/25 - Miss
KURA
Sec Filings
- 12/2/25 - Form 8-K
- 11/14/25 - Form 144
- 11/14/25 - Form 4
- KURA's page on the SEC website